Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
about
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseThe Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-AnalysisInsights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesThe outdoor air pollution and brain health workshopMultiple system atrophy: a clinical and neuropathological perspectiveGlia and alpha-synuclein in neurodegeneration: A complex interactionBiochemical premotor biomarkers for Parkinson's diseaseEmerging candidate biomarkers for Parkinson's disease: a reviewPredicting cognitive decline in Parkinson's disease: can we ask the genes?CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's diseaseCerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson DiseasePlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesThe BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohortValue of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosisWhat is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Amyloid is linked to cognitive decline in patients with Parkinson disease without dementiaMetabolomic biomarkers as strong correlates of Parkinson disease progressionPhosphorylated α-synuclein in Parkinson's disease.Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriersClinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.Targeted discovery and validation of plasma biomarkers of Parkinson's disease.Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's DiseaseThe role of biomarkers and imaging in Parkinson's disease.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.Towards translational therapies for multiple system atrophyLevels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's diseaseAnalysis of extracellular RNA in cerebrospinal fluidCerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directionsElevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy.Atypical parkinsonism: an update.Different patterns of cytokines and chemokines combined with IFN-γ production reflect Mycobacterium tuberculosis infection and disease.Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathiesPhosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity
P2860
Q26744782-B63491F9-626E-4F38-8DF8-53D2B7082F5EQ26785974-7767FE8C-6E10-469B-ACD4-D556EA1DE6BDQ26795984-FCEF164F-1599-40E1-833F-A1A67D840257Q26823021-53CE32F3-9AC4-4432-84D5-97503BA2FD3FQ26829838-DD38079C-A4BE-4493-91C8-94BCA6AA7688Q26851153-EC82052D-4279-4FF7-BD9E-E7555FA1E72DQ27008467-8DC1F4FE-3911-4563-94CA-C9AC45328D5EQ27015018-97106D19-2E4D-4256-A4F3-F586B6058C81Q27025463-ED0750BF-0CDC-440D-AB21-54A5B00BCD35Q27304608-919F625D-9A48-42F8-AD16-AECECE2DA45EQ27311994-56468691-9E21-4449-AB1E-F2DF3337AECAQ27314618-95C9F3F7-73C9-4480-93D5-418705E48253Q27322563-882A1986-CB08-47B1-970D-BE537984F52CQ27333599-E21C11DA-0C76-4391-AF0A-00EC9D73AA29Q27686837-22EC9C95-0752-432C-9A99-07556A869D11Q28072061-6E14BB54-F9ED-43DE-85D4-8A520CBAB076Q28076121-DBEC29FF-5730-4DE4-8477-66AC11EF04DCQ28082380-1E00AF56-0B8E-4CA9-A0FF-5EFFC19A714CQ28083203-FB7E0517-229E-43A4-8448-04396D494D3FQ28705235-54975F87-4117-4C01-8D3F-E3500A087C1EQ29248111-3FF62BDF-DA48-46FB-BFAB-7F48A05D955BQ30510167-8D56CC1D-B4B5-4F67-B0BC-EB85D4C0F5F1Q30525550-ABC64FBA-2033-4C5E-B603-B87C0967DE55Q30544056-7B13AB81-C0FB-4FFC-87D7-9B67B3D1D5E9Q30597182-DB217ED5-6DE7-4E0F-BFEB-5D0521C6D73DQ30659251-F0A8F9D6-CC2C-412C-86D9-7A26E9969EB6Q31041660-46F40FD3-98C3-4647-AAFA-082434639D74Q33666297-2E448363-CB68-48DC-8867-6C1B35FC1B5CQ33705614-7DD1F1B1-2310-44AF-9874-0C48FE4F1BF7Q33797532-6825E9EE-16AF-4766-A15E-C37A8182AD42Q33822641-E4187CC3-FA4D-4984-A96F-9CD4B28EBC43Q33893280-C6CB8822-7FF0-4996-96F7-D76B21D0A680Q34237637-4C897600-1913-468B-9041-6A831A5FCA35Q34242682-D5B06CF1-4850-4636-B281-B89461C501A8Q34295261-4A229DD9-18D5-463A-9E22-66480A1F9499Q34337714-363B9372-016A-41D1-9F9F-B1FBC58E2433Q34427734-C3BDB992-7E52-4282-9694-BB225240C744Q34438204-70118806-07CF-4651-8C83-778699F8AACDQ34450431-5B52926D-866C-48AE-86B6-82C59A2C69EFQ34460662-09BCFEAA-8A9B-42B3-B726-E02AABBEF537
P2860
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@ast
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@en
type
label
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@ast
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@en
prefLabel
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@ast
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
@en
P2093
Aneeka M Hancock
Carmen Ginghina
David Goldstein
Douglas Galasko
Elaine R Peskind
Hojoong M Kim
James B Leverenz
Joshua Bradner
Kathryn A Chung
P2860
P304
P356
10.1002/ANA.22311
P577
2011-03-11T00:00:00Z